Malignant glioma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 18, Issue SUPPL. 2, 2007, Pages

  Stupp, R ^a,b  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b ESMO HEAD OFFICE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NITROSOUREA; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ADJUVANT THERAPY; ARTICLE; BRAIN BIOPSY; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; FOLLOW UP; GLIOBLASTOMA; HUMAN; LUMBAR PUNCTURE; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE FRACTIONATION; RISK ASSESSMENT; TREATMENT OUTCOME; TREATMENT PLANNING;

BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; GLIOMA; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT;

EID: 40849147054     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm044     Document Type: Article

References (17)

1. Brandes AA, Tosoni A, Basso U et al. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: A phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol 2004; 22: 4727-4734.
2. DeAngelis LM. Medical progress: Brain tumors. N Engl J Med 2001; 344: 114-123.
3. Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.
4. Jaeckle KA, Ballman KV, Rao RD et al. Current strategies in treatment of oligodendroglioma: Evolution of molecular signatures of response. J Clin Oncol 2006; 24: 1246-1252.
5. Kleihues P, Louis DN, Scheithauer BW et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002; 61: 215-225.
6. Lacroix M, Abi-Said D, Fourney DR et al. A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. J Neurosurg 2001; 95: 190-198.
7. Macdonald DR, Cascino TL, Schold SC Jr, Caimcross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8: 1277-1280.
8. Medical Research Council Brain Tumor Worlking Party. Randomized trial of procarbazine, lomustine and vincristine in the adjuvant treatment of high-grade astrocytoma: A Medical Research Council trial. J Clin Oncol 2001; 19: 509-518.
9. Roa A Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patents with glioblastoma multiforme: A prospective randomized clinical trial. J Clin Oncol 2004; 22: 1583-1588.
10. Stewart LA. Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002; 359: 1011-1018.
11. Stupp R, Hegi ME, van den Bent MJ et al. Changing paradigms - an update of the multidisciplinary management of malignant glioma. Oncologist 2006; 11: 165-180.
12. Stupp R, Mason WP, van den Bent MJ et al. Concomitant and adjuvant temozotomide and radiotherapy for newly diagnosed glioblastoma multiforme. N Engl J Med 2005; 352: 987-996.
13. van den Bent MJ, Taphoorn MJ, Brandes AA et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 2003; 21: 2525-2528.
14. Westphal M, Hilt DC, Bortey E et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncol 2003; 5: 79-88.
15. Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999; 17: 2572-2578.
16. Wood A Green SB, Shapiro WR. The prognostic importance of tumor size in malignant gliomas: A computed tomographic scan study by the Brain Tumor Cooperative Group. J Clin Oncol 1988; 6: 338-343.
17. Yung WK, Albright RE, Olson J et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000; 83: 588-593.